The Moderna NEXSPIKE COVID-19 vaccine is a new, low-dose vaccine approved by the FDA on May 31, 2025, for individuals 65 and older, as well as those between 12 and 64 years old with underlying health risks. OFFICIALLY: This vaccine offers a more targeted immune response and is designed to provide enhanced protection against COVID-19, particularly for high-risk populations. Key Features: - Dosage: One-fifth of the dose used in Moderna's current COVID-19 vaccine, Spikevax - Ta